Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd    600332   CNE000001733

GUANGZHOU BAIYUNSHAN PHRMCL HLDGS CO LTD

(600332)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
05/16/2019 05/17/2019 05/20/2019 05/21/2019 05/22/2019 Date
44.4(c) 42.97(c) 42.24(c) 42.58(c) 41.28(c) Last
12 709 024 13 666 253 13 662 645 10 531 616 15 752 346 Volume
+0.50% -3.22% -1.70% +0.80% -3.05% Change
More quotes
Financials (CNY)
Sales 2019 55 778 M
EBIT 2019 3 496 M
Net income 2019 3 362 M
Finance 2019 11 833 M
Yield 2019 1,32%
Sales 2020 60 798 M
EBIT 2020 3 988 M
Net income 2020 3 908 M
Finance 2020 14 476 M
Yield 2020 1,50%
P/E ratio 2019 21,14
P/E ratio 2020 18,28
EV / Sales2019 1,71x
EV / Sales2020 1,53x
Capitalization 107 B
More Financials
Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is engaged in the pharmaceutical and healthcare industry. The Company's segments are Great Southern TCM, Great Commerce, Great Health and Great Medical Care. The Company's Great South TCM includes research, development, manufacturing and... 
Sector
Pharmaceuticals
Calendar
06/27 | 10:00pmShareholder meeting
More about the company
Surperformance© ratings of Guangzhou Baiyunshan Phrmc
Trading Rating : Investor Rating :
More Ratings
Latest news on GUANGZHOU BAIYUNSHAN PHRMC
05/06GUANGZHOU BAIYUNSHAN PHRMCL HLDGS : Baiyunshan Pharm receives RMB358.29m gov't s..
AQ
04/29GUANGZHOU BAIYUNSHAN PHRMCL HLDGS : Baiyunshan Pharma 1Q net up 55% to RMB1.41bn
AQ
2018GUANGZHOU BAIYUNSHAN PHRMCL HLDGS : Baiyunshan interim net up 126% to RMB2.6b; n..
AQ
2018GUANGZHOU BAIYUNSHAN PHARMACEUTICAL : Ex-dividend day for final dividend
FA
2018GUANGZHOU BAIYUNSHAN PHRMCL HLDGS CO : annual earnings release
2017GUANGZHOU BAIYUNSHAN PHARMACEUTICAL : Annual Report
CO
2017GUANGZHOU BAIYUNSHAN PHRMCL HLDGS CO : Ex-dividend day for final dividend
FA
2016GUANGZHOU BAIYUNSHAN PHRMCL HLDGS CO : Ex-dividend day for extraordinary dividen..
FA
2016GUANGZHOU BAIYUNSHAN PHRMCL HLDGS CO : annual earnings release
2015GUANGZHOU BAIYUNSHAN PHRMCL HLDGS CO : Ex-dividend day for final dividend
FA
More news
Analyst Recommendations on GUANGZHOU BAIYUNSHAN PHRMC
More recommendations
Sector news : Pharmaceuticals - NEC
01:04aDAIICHI SANKYO : looking to sell OTC drug unit for about $900 million - Nikkei B..
RE
05/22JOHNSON & JOHNSON : J&J Unit Gets FDA Priority Review of Invokana in Chronic Kid..
DJ
05/22Synlogic to Study SYNB1891 With Roche's Tecentriq in Advanced Solid Tumors
DJ
05/22AMGEN : to Buy Danish Biotech Nuevolution for $167 Million
DJ
05/22SANOFI : French Deal Spree Fueled By Easy Money
DJ
More sector news : Pharmaceuticals - NEC
Chart GUANGZHOU BAIYUNSHAN PHRMCL HLDGS CO LTD
Duration : Period :
Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GUANGZHOU BAIYUNSHAN PHRMC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 47,3  CNY
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Hong Li General Manager & Director
Chu Yuan Li Chairman
Jia Xiong Xian Chairman-Supervisory Board
Hin Wing Wong Independent Non-Executive Director
Chang Hai Wu Director & Deputy General Manager
Sector and Competitors
1st jan.Capitalization (M$)
GUANGZHOU BAIYUNSHAN PHRMCL HLDGS CO LTD19.07%15 650
JOHNSON & JOHNSON7.03%367 513
PFIZER-4.54%231 237
ROCHE HOLDING LTD.9.70%226 519
NOVARTIS12.54%207 417
MERCK AND COMPANY4.04%203 088